Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

AU:BOT Stock Latest News

Company AnnouncementsBotanix sets 2026 AGM to vote on pay report and director re-election4d ago

Company AnnouncementsBotanix Pharmaceuticals Seeks ASX Quotation for New Share Issue5d ago
Company AnnouncementsBotanix’s Latest Investor Update Emphasises Risk and Regulatory Caution6d ago
Company AnnouncementsBotanix Pharmaceuticals Appoints New Director With No Current Shareholdings2w ago
Company AnnouncementsBotanix Discloses Director Daniel Sharp’s Exit and Indirect Holdings2w ago

Botanix refreshes board with interim Australian directors after resignations

Company AnnouncementsBotanix refreshes board with interim Australian directors after resignations2w ago

Company AnnouncementsBotanix Sets 2026 AGM Date as Governance Milestones Align with Sofdra Push1M ago

Company AnnouncementsBotanix Director Increases Equity Stake via Performance Rights Conversion1M ago

Company AnnouncementsBotanix seeks ASX quotation for 24.9 million new shares1M ago
Company AnnouncementsS&P Dow Jones Indices Unveils September 2026 Rebalance of S&P/ASX Benchmarks1M ago
Company AnnouncementsBotanix Updates Director Patricia Walker’s Equity Holdings After Option Expiry2M ago
Company AnnouncementsBotanix Pharmaceuticals Options Lapse, Streamlining Capital Structure2M ago

Botanix Pharm: Strong Sofdra Adoption and Margin Upside Support Buy Rating with Unchanged $1 Price Target

RatingsBotanix Pharm: Strong Sofdra Adoption and Margin Upside Support Buy Rating with Unchanged $1 Price Target2M ago

Company AnnouncementsBotanix files updated ASX corporate governance statement for 20262M ago

Company AnnouncementsBotanix Revenue Surges on Sofdra Launch as Loss Narrows2M ago

Company AnnouncementsBotanix Issues 14 Million Unquoted Performance Rights Under Incentive Plan2M ago
Company AnnouncementsBotanix Pharmaceuticals Adds 2.3 Million Shares to ASX Quotation2M ago
Company AnnouncementsBotanix Pharmaceuticals Updates Market on Lapsing of 3.25 Million ASX Options3M ago
RatingsBotanix: Sofdra Launch Momentum and Revenue Recovery Support Unchanged $1 Price Target and Buy Rating3M ago

Botanix boosts Sofdra sales, tightens costs and fortifies IP as cash position strengthens

Company AnnouncementsBotanix boosts Sofdra sales, tightens costs and fortifies IP as cash position strengthens3M ago

Company AnnouncementsBotanix Seeks ASX Quotation for 10.3 Million New Shares5M ago

Company AnnouncementsBotanix Securities Lapse Trims Potential Share Dilution5M ago